Bruker Daltonics to Present at the International Mass Spectrometry Conference (IMSC) in Prague on Clinical Proteomics, MALDI Imaging, Ion Trap ETD, FTMS and Metabolomics.

PRAGUE, Czech Republic -- At the 2006 International Mass Spectrometry Conference, Bruker Daltonics will make numerous presentations on mass spectrometry applications in proteomics and clinical research solutions, as well as in small molecule analysis and metabolomics. On Tuesday, August 29, 2006, top Bruker Daltonics scientists will lead in-depth discussions of the following topics at a luncheon seminar from 1:15 to 2:15 p.m. in Meeting Room 1, 1st Floor, in the Prague Congress Centre. Space is limited, so RSVP early by registering at www.bdal.com or by emailing to [e-mail]

Clinical Biomarker Discovery Integrated with MALDI Molecular Imaging:

an in-depth analysis of Bruker Daltonics' integrated solution for biomarker screening, identification and imaging in clinical tissue research. We introduce "class imaging" vs. mass imaging, which enables the sensitive detection of novel clinically important protein or peptide biomarkers in diseases such as cancer by tissue molecular imaging analysis.

New Frontiers in Ion Trap ETD:

having introduced ETD (electron transfer dissociation) in 2005 as the first vendor, Bruker Daltonics is now taking the next major step forward: data-dependent, intelligent combinations of CID and ETD on an HCT Ultra(TM) high-capacity ion trap for maximum information on sequence coverage and post-translational modifications in complex samples will be described.

New Tools for "Top-down" Detailed Protein Characterization

The Bruker Daltonics apex-Qe hybrid FTMS is ideally suited to probe the chemical and structural nature of intact proteins. Features such as selected ion enrichment (SIE(TM)) followed by CID, IRMPD, and ECD provide researchers with incredible flexibility and unparalleled resolution and accuracy. Bruker has extended the capabilities of "top-down" strategies even further with the addition of new algorithms that include: monoisotopic peak-finder, improved charge deconvolution, and database searching. The utility of these tools will be demonstrated with highly relevant protein characterization examples.

Integrated Metabolic Profiling Elucidated

With its unique integrated, hyphenated LC-NMR/ESI-TOF setup in combination with statistical methods, Bruker Daltonics presents the ultimate solution for the full characterization of complex metabolic profiles and for small molecule biomarker discovery. This unique hyphenated solution and its various advantages will be demonstrated.

In addition, over 40 other oral and poster presentations by Bruker Daltonics scientists and customers will demonstrate the Company's wide range of high performance life-science mass spectrometers. The Company also anticipates making several product introductions during IMSC. For further information on IMSC, please visit www.imsc2006.org

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of nuclear, biological and chemical (NBC) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.